Axxam and the Neurodegeneration Consortium at The University of Texas MD Anderson Cancer Center collaborate on a novel approach to Alzheimer’s disease research
Axxam SpA (Milan/Italy) announced today that it has entered into a research collaboration with the Neurodegeneration Consortium (NDC) at The University of Texas MD Anderson Cancer Center (MD Anderson). The aim of the collaboration is to identify and develop novel small molecule modulators of an undisclosed G-protein coupled receptor linked to Alzheimer’s disease.